RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study
- RAPT Therapeutics Inc (NASDAQ: RAPT) has announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).
- After four weeks of treatment, patients with moderate-to-severe AD who received RPT193 showed a 36.3% improvement from baseline in the Eczema disease severity score, compared to 17.0% in the placebo group.
- Notably, in the two weeks following the end of treatment, the RPT193 group showed continued improvement and further separation from placebo with a 53.2% improvement in EASI at the six-week time point compared to 9.6% in the placebo group.
- 42.9% of patients treated with RPT193 achieved a 50% improvement in EASI score (EASI-50) compared with 10.0% in the placebo group.
- 45.0% of patients treated with RPT193 achieved at least a four-point reduction in the pruritus (itch) score, compared with 22.2% in the placebo group.
- RPT193 was well tolerated in the Phase 1b study. No serious adverse events were reported, and all adverse events reported were mild or moderate in intensity.
- The company plans to initiate a dose-ranging Phase 2b study in moderate-to-severe AD and a Phase 2a study in asthma.
- Price Action: RAPT shares are up 67.3% at $31.06 during the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Biotech Long Ideas News Health Care Small Cap FDA Movers Trading Ideas Best of Benzinga
